```html

Radiodermatitis – A Complete Patient‑Focused Guide

Overview

Radiodermatitis (also called radiation dermatitis) is an inflammatory skin reaction that occurs after exposure to ionizing radiation. It most commonly develops in patients receiving external‑beam radiation therapy (EBRT) for cancer, but it can also follow brachytherapy, radioisotope therapy, or accidental occupational exposure.

Who it affects: Anyone undergoing therapeutic radiation to the skin or to underlying structures can develop radiodermatitis. The condition is seen in roughly 70–90% of patients receiving curative‑dose radiation, with severity ranging from mild erythema to severe ulceration.

Prevalence: According to a 2021 systematic review, up to 95% of breast‑cancer patients and 80% of head‑and‑neck cancer patients experience some degree of skin change during treatment.<sup>1</sup> The incidence is lower (<10–20%) in patients receiving low‑dose palliative regimens.

Symptoms

Radiodermatitis usually follows a predictable timeline that mirrors the cumulative radiation dose. Symptoms can be divided into acute (weeks to months after exposure) and chronic (months to years later).

Acute Symptoms

• Erythema (redness): Appears 1–3 weeks after starting therapy, similar to a mild sunburn.
• Dry desquamation: Flaky or scaling skin that may feel tight or itchy.
• Moist desquamation: Weeping, weepy patches where the epidermis has broken down.
• Edema (swelling): Soft tissue swelling in the irradiated field.
• Pruritus (itching): Often accompanies dryness.
• Pain or burning sensation: Varies from mild discomfort to severe pain.
• Hyperpigmentation or hypopigmentation: Darkening or lightening of the skin can begin during treatment.

Chronic Symptoms (months to years after therapy)

• Fibrosis: Thickened, indurated skin that may restrict movement.
• Telangiectasia: Visible small blood vessels giving a “spider‑vein” appearance.
• Persistent hyper‑ or hypopigmentation.
• Atrophy: Thinning of the skin, sometimes leading to ulceration.
• Radiation‑induced secondary skin cancers: Rare but serious, usually appearing >5 years post‑treatment.

Causes and Risk Factors

Primary Cause

Radiodermatitis is caused by DNA damage and oxidative stress in skin cells from ionizing radiation. This triggers an inflammatory cascade involving cytokines (e.g., TNF‑α, IL‑1), leading to epidermal breakdown and vascular changes.

Key Risk Factors

• Radiation dose & fractionation: Higher total dose (>50 Gy) and larger single fractions increase risk.
• Treatment area: Skin folds (e.g., inframammary, axillary), scalp, and mucosal surfaces are more susceptible.
• Patient‑related factors:
  • Skin type – Fitzpatrick III–VI have higher pigment‑related reactions.
  • Age – Elderly skin is thinner; children have more rapid cell turnover.
  • Smoking – Impairs microvascular repair.
  • Diabetes, vascular disease, or connective‑tissue disorders (e.g., scleroderma).
  • Obesity – Increases friction and moisture.
• Concurrent therapies: Chemotherapy (especially taxanes, anthracyclines), targeted agents (EGFR inhibitors), and immunotherapy can potentiate skin toxicity.
• Previous radiation: Re‑irradiation significantly raises severity.
• Skin care practices: Harsh soaps, alcohol‑based rubs, and tight clothing can exacerbate damage.

Diagnosis

Radiodermatitis is a clinical diagnosis made by reviewing the patient’s treatment history and performing a focused skin examination.

Steps in the Diagnostic Process

1. History: Radiation dose, fractionation schedule, field size, concurrent medications, and onset of skin changes.
2. Physical exam: Assessment of erythema, desquamation, ulceration, and extent (using the Common Terminology Criteria for Adverse Events – CTCAE v5.0).
3. Photography: Baseline and serial photographs help track progression.
4. Biopsy (rare): Indicated when infection, malignancy, or atypical ulceration is suspected. Histology shows epidermal necrosis, dermal inflammation, and vascular changes.
5. Adjunct tests (if needed):
   • Swab cultures for secondary bacterial/fungal infection.
   • Ultrasound or MRI to evaluate deep tissue involvement in severe cases.

Treatment Options

Management focuses on preventing progression, relieving symptoms, and promoting healing. Treatment is tailored to the CTCAE grade.

General Skin‑Care Principles (All Grades)

• Gentle cleansing with lukewarm water and mild, fragrance‑free soap.
• Pat dry; avoid rubbing.
• Apply a hypoallergenic, fragrance‑free moisturizer (e.g., petrolatum, silicone‑based ointments) at least twice daily.
• Wear loose, breathable clothing; avoid friction.
• Protect the treated area from sun exposure (broad‑spectrum SPF 30+).

Pharmacologic & Procedural Interventions

CTCAE Grade	Recommended Treatment
Grade 1 (mild erythema, dry desquamation)	Emollient creams (e.g., 5% urea lotion). Topical corticosteroid—low potency (hydrocortisone 1%) twice daily if itching.2
Grade 2 (moderate erythema, brisk desquamation, mild pain)	Mid‑potency topical steroid (e.g., triamcinolone 0.1% BID). Barrier film (e.g., silicone‑gel or zinc oxide) to protect weeping sites. Oral analgesics (acetaminophen or NSAIDs) as needed.
Grade 3 (moist desquamation, ulceration, severe pain)	High‑potency steroid (clobetasol 0.05% BID) for limited areas; monitor for atrophy. Hydrocolloid or alginate dressings to maintain a moist wound environment. Topical silver sulfadiazine 1% if infection suspected. Systemic analgesia (opioids per WHO ladder) and consider gabapentin for neuropathic pain. Referral to a wound‑care specialist.
Grade 4 (life‑threatening necrosis, deep ulceration)	Urgent multidisciplinary care (radiation oncology, dermatology, plastic surgery). Surgical debridement and possible flap reconstruction. Broad‑spectrum antibiotics if cellulitis or osteomyelitis. Hyperbaric oxygen therapy in select centers (benefits reported in RCTs).3

Adjunct Therapies with Emerging Evidence

• Topical melatonin cream: Antioxidant properties; small pilot trial showed reduced erythema.<sup>4</sup>
• Calendula officinalis ointment: Mixed results; may improve moist desquamation in breast‑cancer patients.<sup>5</sup>
• Low‑level laser therapy (LLLT): May accelerate healing of chronic ulceration; evidence limited.

Living with Radiodermatitis

Skin changes can affect daily life, self‑image, and quality of life. Below are practical tips to help patients cope.

Skincare Routine

1. Apply moisturizer immediately after bathing (the “wet‑skin” technique).
2. Use a clean, soft towel; avoid towel‑drying over the irradiated area.
3. Carry a small tube of steroid cream for itching bursts.
4. Switch to hypoallergenic detergents and avoid fabric softeners.

Clothing & Lifestyle

• Choose loose‑fitting, natural‑fiber garments (cotton, bamboo).
• For head‑and‑neck radiation, wear a soft, breathable hat or scarf to protect the scalp.
• Hydrate well (≥2 L water per day) to support skin integrity.
• Limit activities that cause friction or excessive sweating (e.g., long bike rides) during peak skin toxicity.

Pain & Itch Management

Over‑the‑counter options are often sufficient for mild symptoms. For persistent discomfort, discuss the following with your clinician:

• Topical lidocaine 5% patches.
• Oral antihistamines (cetirizine) for pruritus.
• Gabapentin or pregabalin for neuropathic pain.

Emotional Support

Visible skin changes can be distressing. Consider:

• Joining a support group for cancer patients on radiation.
• Speaking with a mental‑health professional if anxiety or depression arises.
• Using photo‑documentation to track improvement, which can be reassuring.

Prevention

While radiation itself cannot be avoided, several strategies can lower the likelihood or severity of radiodermatitis.

• Advanced radiation techniques: Intensity‑modulated radiation therapy (IMRT), proton therapy, and image‑guided radiation reduce dose to surrounding skin.
• Fractionation: Smaller daily doses (hypofractionation) have been shown to cause less skin toxicity in breast‑cancer protocols.<sup>6</sup>
• Skin preparation: Avoid shaving the treatment area; use electric clippers if hair removal is required.
• Prophylactic moisturizers: Starting a fragrance‑free emollient 1–2 weeks before radiation can improve barrier function.<sup>7</sup>
• Smoking cessation: Improves microvascular healing.
• Nutritional support: Adequate protein (1.2–1.5 g/kg/day) and vitamin C/E supplementation may aid tissue repair (consult a dietitian).

Complications

If radiodermatitis is not adequately managed, the following complications can arise:

• Secondary infection: Bacterial (Staphylococcus aureus, Streptococcus) or fungal infections can progress rapidly, especially with moist desquamation.
• Chronic ulceration: May require surgical closure and can predispose to osteomyelitis when over bone.
• Fibrosis & contracture: Limits range of motion, particularly in joints (e.g., shoulder after breast radiation).
• Psychosocial impact: Chronic pain, disfigurement, and fear of recurrence affect quality of life.
• Radiation‑induced secondary skin cancer: Rare (<1% at 10 years) but warrants lifelong skin surveillance.

When to Seek Emergency Care

---

References

1. Wong, J. et al. “Incidence of acute skin toxicity in patients undergoing curative radiotherapy.” International Journal of Radiation Oncology Biology Physics, 2021; 110(2): 456‑464.
2. Mayo Clinic. “Radiation skin reactions – treatment.” Accessed May 2026. https://www.mayoclinic.org
3. Bennett, M.H. et al. “Hyperbaric oxygen therapy for refractory radiation‑induced tissue injury: a randomized trial.” Cancer, 2020; 126(4): 823‑831.
4. Khorasani, R. et al. “Topical melatonin reduces acute radiation dermatitis in breast cancer patients: a pilot study.” Dermatologic Therapy, 2022; 35(5): e15234.
5. Padhye, S. et al. “Calendula ointment for radiation dermatitis: a systematic review.” Supportive Care in Cancer, 2021; 29(9): 5113‑5122.
6. Association of Breast Cancer Surgeons. “Hypofractionated whole‑breast irradiation and skin toxicity.” JAMA Oncology, 2023; 9(3): 215‑224.
7. NIH National Cancer Institute. “Managing skin side effects of radiation therapy.” Updated 2024. https://www.cancer.gov

```